CME in Minutes: Education in Cardiology & Pulmonology

Please visit answersincme.com/KQK860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Virginia Clark, MD, MS. In this activity, an expert in liver disease discusses practical considerations for identifying and managing liver disease related to alpha-1 antitrypsin deficiency (AATD) across the care continuum. Upon completion of this activity, participants should be better able to: Apply strategies to reach a diagnosis of AATD and associated liver disease; Summarize the evolving treatment landscape for AATD-associated liver disease; and Explain multidisciplinary team approaches to effectively manage patients with AATD-associated liver disease.

Please visit answersincme.com/KQK860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Virginia Clark, MD, MS. In this activity, an expert in liver disease discusses practical considerations for identifying and managing liver disease related to alpha-1 antitrypsin deficiency (AATD) across the care continuum. Upon completion of this activity, participants should be better able to: Apply strategies to reach a diagnosis of AATD and associated liver disease; Summarize the evolving treatment landscape for AATD-associated liver disease; and Explain multidisciplinary team approaches to effectively manage patients with AATD-associated liver disease.

Please visit answersincme.com/860/240201375-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by James Michael Ramsahai, BSc, MD, PhD, FRCPC and Nan Zhao, BSc, MD, FRCPC. In this activity, experts in managing severe eosinophilic asthma discuss evidence-based strategies for personalizing biologic therapy, reducing steroid burden, and optimizing treatment in the setting of overlapping eosinophilic diseases. Upon completion of this activity, participants should be better able to: Identify strategies to individualize the selection of biologic therapies for patients with severe eosinophilic asthma based on the latest clinical and real-world evidence; Evaluate the implications of real-world data on biologic therapies for addressing airway remodeling and airway plugging; Develop steroid-sparing treatment plans and monitoring strategies for patients with severe eosinophilic asthma; and Formulate treatment plans to adjust the use of biologic therapies in patients with severe eosinophilic asthma and overlapping eosinophilic comorbidities.

Please visit answersincme.com/860/MED-CMB-03166-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Samuel S. Gidding, MD; Pamela B. Morris, MD, FACC and Allison Jamison. In this activity, experts in homozygous familial hypercholesterolemia (HoFH) discuss screening, diagnosis, and treatment strategies to support effective management of this rare inherited lipid disorder. Upon completion of this activity, participants should be better able to: Identify strategies to screen and diagnose HoFH; Review the treatment landscape of HoFH, including the role of LDLR-independent therapies; and Outline patient-centered practical strategies to enhance the management of children and adults with HoFH.

Please visit answersincme.com/860/120773-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Alex Spira, MD, PhD, FASCO; and Kathryn C. Arbour, MD. In this activity "In this activity, experts in oncology discuss the evolving role of RAS(ON) inhibitors in shaping future treatment strategies for patients with KRAS-mutated non–small-cell lung cancer (NSCLC). Upon completion of this activity, participants should be better able to: Identify areas of unmet need in KRAS-mutant NSCLC across diverse KRAS variants in pretreated advanced settings; Describe the rationale for the use of RAS(ON) inhibitors for patients with KRAS-mutated NSCLC, based on evidence; and Assess how RAS(ON) inhibitors may be optimally used in clinical practice as they become available.

Please visit answersincme.com/RCG860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Raymond Osarogiagbon, MD, MBBS, FACP, FASCO; and Michael Gieske, MD. In this activity, experts in lung cancer discuss practical strategies for lung cancer screening. Upon completion of this activity, participants should be better able to: Recognize barriers to achieving lung cancer screening for eligible patients; Identify patients at high risk of lung cancer who are eligible for screening; and Outline practical, patient-centered strategies to appropriately integrate lung cancer screening into routine practice.

Please visit answersincme.com/JRV860 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, an expert in lung cancer discusses the use of immunotherapy in clinical practice for patients with limited-stage (LS) and extended-stage (ES) small-cell lung cancer (SCLC). Upon completion of this activity, participants should be better able to: Recognize the rationale for the use of immune checkpoint inhibitors in LS-SCLC and ES-SCLC; Assess the clinical profiles of approved and emerging immune checkpoint inhibitor therapies for LS-SCLC and ES-SCLC; and Outline evidence-based strategies for incorporating immune checkpoint inhibitor therapy into treatment plans for patients with LS-SCLC and ES-SCLC.

Please visit answersincme.com/860/99097105-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in small cell lung cancer (SCLC) discuss the pathophysiologic rationale, emerging clinical evidence, and potential future role for B7-H3–directed antibody-drug conjugates in extensive-stage SCLC. Upon completion of this activity, participants should be better able to: Recognize the rationale for investigating B7-H3–directed antibody-drug conjugates (ADCs) in the treatment of patients with extensive-stage small cell lung cancer (ES-SCLC); Analyze recent clinical trial findings on B7-H3–directed ADCs in patients with previously treated ES-SCLC; and Formulate evidence-based, multidisciplinary team strategies for incorporating B7-H3–directed ADCs into treatment plans for patients with ES-SCLC, as they become available.

Please visit answersincme.com/860/MED-RESP-03658-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in pulmonary medicine discuss how to integrate biologics into individualized treatment plans for chronic obstructive pulmonary disease (COPD), featuring insights from a patient advocate. Upon completion of this activity, participants should be better able to: Specify the rationale for targeting eosinophilic inflammation in COPD; Differentiate available and late-stage emerging biologic therapies based on the latest clinical evidence in COPD; Identify patients with COPD who are appropriate candidates for biologic therapy; and Outline strategies to optimally incorporate biologic therapies into treatment plans for patients with COPD.

Please visit answersincme.com/860/99224979-replay1 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss the latest data on emerging B7-H3–directed antibody–drug conjugates (ADCs) for the treatment previously treated extensive-stage small-cell lung cancer (ES-SCLC). Upon completion of this activity, participants should be better able to: Specify how B7-H3 overexpression is relevant to ES-SCLC prognosis and treatment; Interpret the clinical evidence for emerging B7H3–directed ADCs in patients with previously treated ES-SCLC; and Translate current evidence and clinical considerations for B7-H3–targeted ADCs into treatment algorithms for patients with ES-SCLC.